FDA Staff Questions Benefits of Glaxo, Merck Cancer Drugs

GlaxoSmithKline Plc. and Merck & Co. and Ariad Pharmaceuticals Inc.’s drugs for a rare, often deadly form of cancer may not offer enough benefits to be worth risks including heart and kidney ailments, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.